COVID-19 Therapy (Moderate)
Phase 3 (Expanded Access)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: Remdesivir in Moderate COVID-19
ClinicalTrial.gov (NCT04292730): Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
WHAT IS THE CATALYST EVENT?
Submit the full data for publication in the upcoming weeks
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
June 1, 2020 Phase 3 Results (Moderate COVID-19)
HC updated 6/16/20
#GILD, #remdesivir, #covid19
(2020) Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. Journal of Korean medical science, 35(6).
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post